Time For AI To Deliver In Drug Discovery, Says Atomwise CEO

 
• By Kevin Grogan

Having signed a multi-year, multi-target agreement with Lilly worth potentially $550m, Atomwise CEO Abe Heifets tells Scrip the burden of proof is on AI practitioners to start producing relevant and actionable data.

Data
Lilly signs AI pact with Atomwise • Source: Shutterstock

More from AI

More from Digital Technologies